A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs SLV 354 (Primary)
- Indications CNS disorders; Cognition disorders
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 16 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Jun 2010 New trial record